Literature DB >> 19633580

Spontaneous regression of metastases from melanoma: review of the literature.

Louise Vennegaard Kalialis1, Krzysztof T Drzewiecki, Helle Klyver.   

Abstract

Regression of metastatic melanoma is a rare event, and review of the literature reveals a total of 76 reported cases since 1866. The proposed mechanisms include immunologic, endocrine, inflammatory and metastatic tumour nutritional factors. We conclude from this review that although the precise mechanisms remain unknown, some event must trigger the immune system to produce a stronger than normal response that results in regression of the melanoma metastases. Immunologic studies of patients with regression may disclose the underlying mechanisms and lead to new therapies of disseminated melanoma.

Entities:  

Mesh:

Year:  2009        PMID: 19633580     DOI: 10.1097/CMR.0b013e32832eabd5

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  63 in total

1.  Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

Authors:  Trudy Straetemans; Cor Berrevoets; Miriam Coccoris; Elike Treffers-Westerlaken; Rebecca Wijers; David K Cole; Valerie Dardalhon; Andrew K Sewell; Naomi Taylor; Jaap Verweij; Reno Debets
Journal:  Mol Ther       Date:  2014-11-03       Impact factor: 11.454

Review 2.  Prognostic significance of autoimmunity during treatment of melanoma with interferon.

Authors:  Michal T Krauze; Ahmad Tarhini; Helen Gogas; John M Kirkwood
Journal:  Semin Immunopathol       Date:  2011-01-31       Impact factor: 9.623

3.  A case report of putative autoimmunity to prostate cancer after immune-mediated rejection of melanoma through a shared tumor antigen.

Authors:  Polly Gregor; Q Daisy Huang; Humilidad F Gallardo; Teresa S Rasalan; Michael J Morris
Journal:  Clin Genitourin Cancer       Date:  2012-01-27       Impact factor: 2.872

4.  The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.

Authors:  Richard P Junghans
Journal:  Cancer Gene Ther       Date:  2017-03       Impact factor: 5.987

Review 5.  Immune checkpoint inhibitors in melanoma.

Authors:  Adam J Cooper; Matteo S Carlino; Richard F Kefford
Journal:  Melanoma Manag       Date:  2015-08-10

Review 6.  Spontaneous regression of pancreatic cancer: real or a misdiagnosis?

Authors:  Marta Herreros-Villanueva; Elizabeth Hijona; Angel Cosme; Luis Bujanda
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

Review 7.  Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.

Authors:  Teresa C Longoria; Krishnansu S Tewari
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-08-16       Impact factor: 4.481

8.  Targeting tumor-resident mast cells for effective anti-melanoma immune responses.

Authors:  Susanne Kaesler; Florian Wölbing; Wolfgang Eberhard Kempf; Yuliya Skabytska; Martin Köberle; Thomas Volz; Tobias Sinnberg; Teresa Amaral; Sigrid Möckel; Amir Yazdi; Gisela Metzler; Martin Schaller; Karin Hartmann; Benjamin Weide; Claus Garbe; Hans-Georg Rammensee; Martin Röcken; Tilo Biedermann
Journal:  JCI Insight       Date:  2019-10-03

9.  Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.

Authors:  Muhammad Khattak; Rosalie Fisher; Samra Turajlic; James Larkin
Journal:  Ther Adv Med Oncol       Date:  2013-03       Impact factor: 8.168

10.  Characterization of three newly established rat sarcoma cell clones.

Authors:  Monika Holubova; Martin Leba; Markéta Sedmikova; Luca Vannucci; Vratislav Horak
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-11-13       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.